Engineered PLGA nano- and micro-carriers for pulmonary delivery: Challenges and promises

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 9, 2012, Pages 1217-1235

  Ungaro, Francesca ^a   D'Angelo, Ivana ^a   Miro, Agnese ^a   La Rotonda, Maria I ^a   Quaglia, Fabiana ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

microparticle; nanoparticle; poly(lactic co glycolic acid); pulmonary delivery

Indexed keywords

ARD 3100; AZTREONAM LYSINE; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CALCITONIN; CIPROFLOXACIN; COLISTIMETHATE; DESLORELIN; DORNASE ALFA; DRUG CARRIER; FENOTEROL; FENTANYL; FLUTICASONE PROPIONATE; FORMOTEROL; GLUCAGON LIKE PEPTIDE; INSULIN; INTERLEUKIN 2; IPRATROPIUM BROMIDE; LANCOVUTIDE; LEVOFLOXACIN; MICROCARRIER; MKC 253; NANOCARRIER; PIRBUTEROL; POLYGLACTIN; RIFAMPICIN; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; TOBRAMYCIN; TRYPSIN INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ASTHMA; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; METERED DOSE INHALER; NANOENGINEERING; NEBULIZER; NONHUMAN; OSTEOPOROSIS; PAIN; PARTICLE SIZE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POWDER INHALER; RESPIRATORY TRACT DISEASE; REVIEW;

ADMINISTRATION, INHALATION; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; LUNG; MICROSPHERES; NANOMEDICINE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; POLYGLYCOLIC ACID; RESPIRATORY MUCOSA; TECHNOLOGY, PHARMACEUTICAL;

EID: 84864719781     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01486.x     Document Type: Review

References (131)

1. Weers JG, et al,. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv 2010; 23 (Suppl. 2): S5-23. S5-23.
2. Newman S, et al,. Respiratory Drug Delivery: Essential Theory & Practice. Richmond, VA: RDD Online, 2009.
3. Onoue S, et al,. New treatments for chronic obstructive pulmonary disease and viable formulation/device options for inhalation therapy. Expert Opin Drug Deliv 2009; 6: 793-811.
4. Ibrahim BM, et al,. Challenges and advances in the development of inhalable drug formulations for cystic fibrosis lung disease. Expert Opin Drug Deliv 2011; 8: 451-466.
5. Patton JS, Byron PR,. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007; 6: 67-74. (Pubitemid 46020287)
6. Misra A, et al,. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb) 2011; 91: 71-81.
7. Patton JS, et al,. The particle has landed-characterizing the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv 2010; 23 (Suppl. 2): S71-S87. S71-S87.
8. Salama R, et al,. Recent advances in controlled release pulmonary therapy. Curr Drug Deliv 2009; 6: 404-414.
9. Pilcer G, Amighi K,. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392: 1-19.
10. Chow AH, et al,. Particle engineering for pulmonary drug delivery. Pharm Res 2007; 24: 411-437. (Pubitemid 46295160)
11. Edwards DA, et al,. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871. (Pubitemid 27443665)
12. Rytting E, et al,. Biodegradable polymeric nanocarriers for pulmonary drug delivery. Expert Opin Drug Deliv 2008; 5: 629-639. (Pubitemid 351998253)
13. Kurmi BD, et al,. Micro- and nanocarrier-mediated lung targeting. Expert Opin Drug Deliv 2010; 7: 781-794.
14. Shoyele SA, Cawthorne S,. Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 2006; 58: 1009-1029. (Pubitemid 44712022)
15. Mohamed F, van der Walle CF,. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J Pharm Sci 2008; 97: 71-87.
16. Global Strategy for the Diagnosis, Management and Prevention of COPD. [Global Initiative for Chronic Obstructive Lung Disease (GOLD) web site]. 2010. Available at: http://www.goldcopd.org/.
17. Global Strategy for Asthma Management and Prevention. [Global Initiative for Asthma (GINA) web site]. 2010. Available at: http://www.ginasthma.org/.
18. Seguin RM, Ferrari N,. Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 2009; 18: 1505-1517.
19. Parry-Billings M, et al,. Oligonucleotides: new therapeutic approaches for asthma and chronic obstructive pulmonary disease. Curr Opin Investig Drugs 2010; 11: 1276-1285.
20. Heijerman H, et al,. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8: 295-315.
21. Geller DE, et al,. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 183: 1510-1516.
22. Geller DE, et al,. Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects. Antimicrob Agents Chemother 2011; 55: 2636-2640.
23. Geller DE, et al,. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere technology. J Aerosol Med Pulm Drug Deliv 2011; 24: 175-182.
24. Pettit RS, Johnson CE,. Airway-rehydrating agents for the treatment of cystic fibrosis: past, present, and future. Ann Pharmacother 2011; 45: 49-59.
25. Martin SL, et al,. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol 2006; 41: 177-183. (Pubitemid 43165448)
26. Griese M, et al,. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 240-250. (Pubitemid 46231900)
27. Brand P, et al,. Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency. Eur Respir J 2009; 34: 354-360.
28. Raghavendran K, et al,. Surfactant therapy for acute lung injury and acute respiratory distress syndrome. Crit Care Clin 2011; 27: 525-559.
29. Alexza Pharmaceuticals. A Growing Pipeline of Promising Staccato Products [Alexza Pharmaceuticals web site]. 2011. Available at: http://www.alexza.com/ products.
30. YMBiosciences Inc. Free and liposome-encapsulated fentanyl: leveraging pulmonary delivery for personalized pain management [Pulmonary drug delivery:new perspectives on inhalers and inhalables web site]. 2007. Available at: http://www.ondrugdelivery.com/publications/Pulmonary-June-07.pdf.
31. Cassidy JP, et al,. Insulin lung deposition and clearance following Technosphere(R) insulin inhalation powder administration. Pharm Res 2011; 28: 2157-2164.
32. Marino MT, et al,. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clin Pharmacol Ther 2010; 88: 243-250.
33. Peyrot M, Rubin RR,. Patient-reported outcomes in adults with type 2 diabetes using mealtime inhaled technosphere insulin and Basal insulin versus premixed insulin. Diabetes Technol Ther 2011; 13: 1201-1206.
34. Tewes F, et al,. Development and characterisation of soluble polymeric particles for pulmonary peptide delivery. Eur J Pharm Sci 2010; 41: 337-352.
35. Baginski L, et al,. Investigations into the fate of inhaled salmon calcitonin at the respiratory epithelial barrier. Pharm Res 2011; 29: 332-341.
36. Codrons V, et al,. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 2003; 92: 938-950. (Pubitemid 36523439)
37. Shoyele SA, et al,. The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalation. AAPS PharmSciTech 2011; 12: 304-311.
38. Shoyele SA,. Controlling the release of proteins/peptides via the pulmonary route. Methods Mol Biol 2008; 437: 141-148. 141-148.
39. Rubin BK,. Air and soul: the science and application of aerosol therapy. Respir Care 2010; 55: 911-921.
40. Carvalho TC, et al,. Influence of particle size on regional lung deposition-what evidence is there? Int J Pharm 2011; 406: 1-10.
41. Bisgaard H, et al,. Drug Delivery to the Lung. New York: Marcel Dekker, 2002.
42. Dolovich MB, Dhand R,. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377: 1032-1045.
43. Hess DR,. Metered-dose inhalers and dry powder inhalers in aerosol therapy. Respir Care 2005; 50: 1376-1383. (Pubitemid 46173325)
44. Geller DE,. Comparing clinical features of the nebulizer, metered-dose inhaler, and dry powder inhaler. Respir Care 2005; 50: 1313-1321. (Pubitemid 46173315)
45. Selroos O, et al,. Use of dry powder inhalers in acute exacerbations of asthma and COPD. Ther Adv Respir Dis 2009; 3: 81-91.
46. Lareau SC, Yawn BP,. Improving adherence with inhaler therapy in COPD. Int J Chron Obstruct Pulmon Dis 2010; 5: 401-406. 401-406.
47. Cryan SA,. Carrier-based strategies for targeting protein and peptide drugs to the lungs. AAPS J 2005; 7: E20-E41.
48. Adi H, et al,. Controlled release antibiotics for dry powder lung delivery. Drug Dev Ind Pharm 2010; 36: 119-126.
49. Ungaro F, et al,. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. J Control Release 2009; 135: 25-34.
50. Sinha VR, Trehan A,. Biodegradable microspheres for protein delivery. J Control Release 2003; 90: 261-280. (Pubitemid 36859959)
51. Mundargi RC, et al,. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008; 125: 193-209.
52. Lai SK, et al,. Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Rev 2009; 61: 158-171.
53. Sanders NN, et al,. Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am J Respir Crit Care Med 2000; 162: 1905-1911.
54. Evora C, et al,. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2- dipalmitoylphosphatidylcholine. J Control Release 1998; 51: 143-152. (Pubitemid 28252865)
55. Csaba N, et al,. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009; 61: 140-157.
56. Olmsted SS, et al,. Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys J 2001; 81: 1930-1937. (Pubitemid 32917145)
57. Tang BC, et al,. Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier. Proc Natl Acad Sci USA 2009; 106: 19268-19273.
58. Mura S, et al,. Biodegradable nanoparticles meet the bronchial airway barrier: how surface properties affect their interaction with mucus and epithelial cells. Biomacromolecules 2011; 12: 4136-4143.
59. Chadwick S, et al,. Delivery strategies to enhance mucosal vaccination. Expert Opin Biol Ther 2009; 9: 427-440.
60. Chadwick S, et al,. Nanotechnology solutions for mucosal immunization. Adv Drug Deliv Rev 2010; 62: 394-407.
61. Lam JK, et al,. Pulmonary delivery of therapeutic siRNA. Adv Drug Deliv Rev. Epub 2011 February 26.
62. Nguyen J, et al,. Fast degrading polyesters as siRNA nano-carriers for pulmonary gene therapy. J Control Release 2008; 132: 243-251.
63. Ungaro F, et al,. Biodegradable particles for local and prolonged delivery of an oligonucleotide decoy to nuclear factor-ÎB in the lung. In:, Dalby RN, et al, ed. RDD Europe 2011. Richmond, VA: RDD Online, 2011: 511-513.
64. Jensen DK, et al,. Design of an inhalable dry powder formulation of DOTAP-modified PLGA nanoparticles loaded with siRNA. J Control Release 2012; 157: 141-148.
65. De Rosa G, et al,. Use of additives in the design of Poly(Lactide-Co- Glycolide) microspheres for drug delivery. In:, Ravi Kumar MNV, ed. Handbook of Particulate Drug Delivery. Stevenson Ranch, CA: American Scientific Publisher, 2008: 61-91.
66. Jain AK, et al,. Engineered PLGA nanoparticles: an emerging delivery tool in cancer therapeutics. Crit Rev Ther Drug Carrier Syst 2011; 28: 1-45.
67. Hamishehkar H, et al,. Pharmacokinetics and pharmacodynamics of controlled release insulin loaded PLGA microcapsules using dry powder inhaler in diabetic rats. Biopharm Drug Dispos 2010; 31: 189-201.
68. Hamishehkar H, et al,. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin. Int J Pharm 2010; 389: 74-85.
69. Devrim B, et al,. Preparation and evaluation of poly(lactic-co-glycolic acid) microparticles as a carrier for pulmonary delivery of recombinant human interleukin-2: II. In vitro studies on aerodynamic properties of dry powder inhaler formulations. Drug Dev Ind Pharm 2011; 37: 1376-1386.
70. Devrim B, et al,. Preparation and evaluation of PLGA microparticles as carrier for the pulmonary delivery of rhIL-2: I. Effects of some formulation parameters on microparticle characteristics. J Microencapsul 2011; 28: 582-594.
71. Yoo NY, et al,. Antioxidant encapsulated porous poly(lactide-co- glycolide) microparticles for developing long acting inhalation system. Colloids Surf B Biointerfaces 2011; 88: 419-424.
72. Koushik K, et al,. Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbetaCD complexes. Pharm Res 2004; 21: 1119-1126. (Pubitemid 38954195)
73. Rawat A, et al,. Inhalable large porous microspheres of low molecular weight heparin: in vitro and in vivo evaluation. J Control Release 2008; 128: 224-232.
74. 1, a pulmonary selective vasodilator. Int J Pharm 2011; 413: 51-62.
75. Gupta V, et al,. Feasibility study of aerosolized prostaglandin E1 microspheres as a noninvasive therapy for pulmonary arterial hypertension. J Pharm Sci 2010; 99: 1774-1789.
76. Kim H, et al,. Albumin-coated porous hollow poly(lactic-co-glycolic acid) microparticles bound with palmityl-acylated exendin-4 as a long-acting inhalation delivery system for the treatment of diabetes. Pharm Res 2011; 28: 2008-2019.
77. Pandey R, et al,. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 2003; 52: 981-986. (Pubitemid 38008419)
78. Thomas C, et al,. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol Pharm 2011; 8: 405-415.
79. Kawashima Y, et al,. Pulmonary delivery of insulin with nebulized DL-lactide/glycolide copolymer (PLGA) nanospheres to prolong hypoglycemic effect. J Control Release 1999; 62: 279-287. (Pubitemid 29486508)
80. Muttil P, et al,. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J 2010; 12: 330-337.
81. Sung JC, et al,. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm Res 2009; 26: 1847-1855.
82. Tomoda K, et al,. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf B Biointerfaces 2009; 71: 177-182.
83. Ungaro F, et al,. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers. J Control Release 2012; 157: 149-159.
84. Kim H, et al,. Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes. Biomaterials 2011; 32: 1685-1693.
85. Malik DK, et al,. Recent advances in protein and peptide drug delivery systems. Curr Drug Deliv 2007; 4: 141-151. (Pubitemid 46557490)
86. Alonso MJ, et al,. Determinants of release rate of tetanus vaccine from polyester microspheres. Pharm Res 1993; 10: 945-953. (Pubitemid 23211414)
87. Zhu G, et al,. Stabilization of proteins encapsulated in injectable poly (lactide- co-glycolide). Nat Biotechnol 2000; 18: 52-57. (Pubitemid 30041172)
88. van de WM, et al,. Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm Res 2000; 17: 1159-1167.
89. van der Walle CF, et al,. Current approaches to stabilising and analysing proteins during microencapsulation in PLGA. Expert Opin Drug Deliv 2009; 6: 177-186.
90. Pistel KF, Kissel T,. Effects of salt addition on the microencapsulation of proteins using W/O/W double emulsion technique. J Microencapsul 2000; 17: 467-483. (Pubitemid 30420829)
91. Ungaro F, et al,. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006; 28: 423-432. (Pubitemid 44038350)
92. Ungaro F, et al,. Engineering gas-foamed large porous particles for efficient local delivery of macromolecules to the lung. Eur J Pharm Sci 2010; 41: 60-70.
93. O'Hara P, Hickey AJ,. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: manufacture and characterization. Pharm Res 2000; 17: 955-961.
94. Suarez S, et al,. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res 2001; 18: 1315-1319. (Pubitemid 32846326)
95. Hirota K, et al,. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J Control Release 2010; 142: 339-346.
96. Doan TV, Olivier JC,. Preparation of rifampicin-loaded PLGA microspheres for lung delivery as aerosol by premix membrane homogenization. Int J Pharm 2009; 382: 61-66.
97. Ohashi K, et al,. One-step preparation of rifampicin/poly(lactic-co- glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J Control Release 2009; 135: 19-24.
98. Pulliam B, et al,. Design of nanoparticle-based dry powder pulmonary vaccines. Expert Opin Drug Deliv 2007; 4: 651-663. (Pubitemid 350193400)
99. Coowanitwong I, et al,. Slow release formulations of inhaled rifampin. AAPS J 2008; 10: 342-348.
100. De Stefano D, et al,. Sustained inhibition of IL-6 and IL-8 expression by decoy ODN to NF-kappaB delivered through respirable large porous particles in LPS-stimulated cystic fibrosis bronchial cells. J Gene Med 2011; 13: 200-208.
101. Dailey LA, et al,. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 2006; 215: 100-108. (Pubitemid 44118400)
102. Hara K, et al,. Histological examination of PLGA nanospheres for intratracheal drug administration. Int J Pharm 2008; 356: 267-273.
103. Rytting E, et al,. In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. J Control Release 2010; 141: 101-107.
104. Beck-Broichsitter M, et al,. Pulmonary targeting with biodegradable salbutamol-loaded nanoparticles. J Aerosol Med Pulm Drug Deliv 2010; 23: 47-57.
105. Hassan MS, Lau R,. Effect of particle formulation on dry powder inhalation efficiency. Curr Pharm Des 2010; 16: 2377-2387.
106. Edwards DA, et al,. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85: 379-385. (Pubitemid 28365799)
107. Arnold MM, et al,. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 2007; 121: 100-109. (Pubitemid 47126070)
108. Kim HK, et al,. Biodegradable polymeric microspheres with 'open/closed' pores for sustained release of human growth hormone. J Control Release 2006; 112: 167-174.
109. Kwon MJ, et al,. Long acting porous microparticle for pulmonary protein delivery. Int J Pharm 2007; 333: 5-9. (Pubitemid 46283284)
110. Yang Y, et al,. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009; 30: 1947-1953.
111. Oh YJ, et al,. Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release 2011; 150: 56-62.
112. Thomas C, et al,. Particle size influences the immune response produced by hepatitis B vaccine formulated in inhalable particles. Pharm Res 2010; 27: 905-919.
113. Giovagnoli S, et al,. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int J Pharm 2007; 333: 103-111. (Pubitemid 46283276)
114. De Rosa G, et al,. Long-term release and improved intracellular penetration of oligonucleotide-polyethylenimine complexes entrapped in biodegradable microspheres. Biomacromolecules 2003; 4: 529-536. (Pubitemid 36701221)
115. Vicennati P, et al,. Polyethylenimine in medicinal chemistry. Curr Med Chem 2008; 15: 2826-2839.
116. De Rosa G, et al,. Poly(lactide-co-glycolide) microspheres for the controlled release of oligonucleotide/polyethylenimine complexes. J Pharm Sci 2002; 91: 790-799. (Pubitemid 34639643)
117. Simberg D, et al,. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit Rev Ther Drug Carrier Syst 2004; 21: 257-317. (Pubitemid 41647579)
118. Andrade F, et al,. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond) 2011; 6: 123-141.
119. Hillaireau H, Couvreur P,. Nanocarriers' entry into the cell: relevance to drug delivery. Cell Mol Life Sci 2009; 66: 2873-2896.
120. Astete CE, Sabliov CM,. Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 2006; 17: 247-289. (Pubitemid 47279194)
121. Mora-Huertas CE, et al,. Polymer-based nanocapsules for drug delivery. Int J Pharm 2010; 385: 113-142.
122. Sung JC, et al,. Nanoparticles for drug delivery to the lungs. Trends Biotechnol 2007; 25: 563-570. (Pubitemid 350138179)
123. Tsapis N, et al,. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci USA 2002; 99: 12001-12005.
124. Gomez-Gaete C, et al,. Dexamethasone acetate encapsulation into Trojan particles. J Control Release 2008; 128: 41-49.
125. Tomoda K, et al,. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf B Biointerfaces 2008; 64: 70-76.
126. Tomoda K, et al,. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf B Biointerfaces 2008; 61: 138-144.
127. Jensen DM, et al,. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J Control Release 2010; 142: 138-145.
128. Yamamoto H, et al,. Engineering of poly(DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. Advanced Powder Technology 2007; 18: 215-228. (Pubitemid 47181968)
129. Baldrick P, Bamford DG,. A toxicological review of lactose to support clinical administration by inhalation. Food Chem Toxicol 1997; 35: 719-733. (Pubitemid 27362037)
130. Wills PJ,. Inhaled mannitol in cystic fibrosis. Expert Opin Investig Drugs 2007; 16: 1121-1126. (Pubitemid 47074166)
131. Yang Y, et al,. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model. Biotechnol Bioeng 2011; 108: 1441-1449.